Volume 14, Issue 4

Neurotherapeutics is now archived and no longer receiving submissions with this publisher. All articles published in the journal during its time with Springer will remain fully searchable through our websites.

Search all Neurotherapeutics articles

October 2017

Current and Future Therapies in Multiple Sclerosis

30 articles in this issue

Letter From the Editor-in-Chief: Journal Transition in the Digital Age
M. Maral Mouradian
Letter 10 October 2017 Pages: 831 - 831
Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead
Devon S. Conway
Le H. Hua
Jeffrey A. Cohen
Editorial 27 September 2017 Pages: 832 - 834
Ocrelizumab and Other CD20⁺ B-Cell-Depleting Therapies in Multiple Sclerosis
Jeffrey M. Gelfand
Bruce A. C. Cree
Stephen L. Hauser
Review 10 July 2017 Pages: 835 - 841
Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis
Laura E. Baldassari
John W. Rose
Review 13 July 2017 Pages: 842 - 858
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
Burhan Z. Chaudhry
Jeffrey A. Cohen
Devon S. Conway
Review 15 August 2017 Pages: 859 - 873
Cladribine to Treat Relapsing Forms of Multiple Sclerosis
Gavin Giovannoni
Review 22 November 2017 Pages: 874 - 887
Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis
Harold L. Atkins
Mark S. Freedman
Review 18 August 2017 Pages: 888 - 893
Remyelinating Pharmacotherapies in Multiple Sclerosis
Riley M. Bove
Ari J Green
Review 25 September 2017 Pages: 894 - 904
The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials
Kedar R. Mahajan
Daniel Ontaneda
Review 02 August 2017 Pages: 905 - 923
Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials
Maria Pia Sormani
Matteo Pardini
Review 10 July 2017 Pages: 924 - 933
Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials
Cindy J. Nowinski
Deborah M. Miller
David Cella
Review 14 September 2017 Pages: 934 - 944
Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics
Lilyana Amezcua
Flavia Nelson
Review 04 August 2017 Pages: 945 - 951
Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions
Andrew L. Smith
Jeffrey A. Cohen
Le H. Hua
Review 26 June 2017 Pages: 952 - 960
Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies
Eric M. L. Williamson
Joseph R. Berger
Review 14 September 2017 Pages: 961 - 973
Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding
Rhonda Voskuhl
Callene Momtazee
Review 01 August 2017 Pages: 974 - 984
Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis
Marisa McGinley
Ian T. Rossman
Review 11 September 2017 Pages: 985 - 998
Wellness and the Role of Comorbidities in Multiple Sclerosis
Brandon P. Moss
Mary R. Rensel
Carrie M. Hersh
Review 07 August 2017 Pages: 999 - 1017
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA
Daniel M. Hartung
Review 15 August 2017 Pages: 1018 - 1026
Therapeutic Approaches for Zika Virus Infection of the Nervous System
Rachel P. M. Abrams
Jamie Solis
Avindra Nath
Current Perspectives 26 September 2017 Pages: 1027 - 1048
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors
Andrew S. Luksik
Russell Maxwell
Michael Lim
Review 03 March 2017 Pages: 1049 - 1065
National Institutes of Health Blueprint Neurotherapeutics Network: Results to Date and Path Forward
Charles L. Cywin
Amir P. Tamiz
Current Perspectives Open access 12 April 2017 Pages: 1066 - 1069
Can a Neurosteroid Ameliorate Fragile X-Associated Tremor/Ataxia Syndrome?
Dejan B. Budimirovic
Commentary 07 September 2017 Pages: 1070 - 1072
Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome
J. Y. Wang
A. M. Trivedi
R. J. Hagerman
Original Article 13 July 2017 Pages: 1073 - 1083
Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort Study
Ariella L. G. Coler-Reilly
Tomoo Sato
Yoshihisa Yamano
Original Article 23 May 2017 Pages: 1084 - 1094
Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor
Marta Miralles
Herena Eixarch
Miguel Chillon
Original Article Open access 07 June 2017 Pages: 1095 - 1106
A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein
Franziska Richter
Sudhakar R. Subramaniam
Gal Bitan
Original Article 05 June 2017 Pages: 1107 - 1119
Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington’s Disease Mice
Sandor Kantor
Janos Varga
A. Jennifer Morton
Original Article Open access 26 June 2017 Pages: 1120 - 1133
Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model
Antonio Leo
Rita Citraro
Emilio Russo
Original Article 26 June 2017 Pages: 1134 - 1147
Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels
Yeri Kim
Jarred M. Griffin
Colin R. Green
Original Article 30 May 2017 Pages: 1148 - 1165
Erratum to: Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington’s Disease Mice
Sandor Kantor
Janos Varga
A. Jennifer Morton
Erratum 25 July 2017 Pages: 1166 - 1166

Volume 14, Issue 4

Search

Navigation